Anne Mensink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne Mensink has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alsya J. Affandi
Department of Molecular Cell Biology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam
2 shared publications - Fred van Leeuwen
Division of Gene Regulation, Netherlands Cancer Institute
2 shared publications - Jip T. van Dinter
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
2 shared publications - Joke M. M. Den Haan
Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
2 shared publications - Willem-Jan de Leeuw
Division of Gene Regulation, Netherlands Cancer Institute
2 shared publications Aru Z Wang
Department of Molecular Cell Biology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam
1 shared publication
Latest Publications
- Open Access
- 18 March 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (6) , e202603624
Histone methyltransferase DOT1L differentially affects the development of dendritic cell subsets
Dendritic cells (DCs) orchestrate immune responses. Their development is controlled by transcription factors, but epigenetic mechanisms remain poorly understood. DOT1L emerges as a key epigenetic regulator in immune cells. Mapping DOT1L-mediated histone H3K79 methylation in canonical DC subsets revealed that DOT1L modified common and DC subset–specific genes. Deletion of Dot1l in vivo or in vitro decreased myeloid progenitors and increased cDC2s, whereas cDC1s remained unchanged. In addition, in vitro deletion of Dot1l led to loss of plasmacytoid DCs (pDCs) and of IFNα production upon stimulation. Upon in vivo deletion, a decrease in pDCs was only observed after subsequent in vitro expansion. This difference was likely related to insufficient replication-mediated loss of H3K79 methylation in vivo within the time frame studied. Transcriptomes of Dot1l -KO DC subsets exhibited enrichment of antigen presentation pathways, and MHC class II surface levels were up-regulated in pDCs. Mechanistically, inhibition of DOT1L linked the observed effects to its methyltransferase activity. Together, our data indicate that in DCs DOT1L differentially affects the development of canonical subsets and suppresses antigen presentation pathways.
- 18 March 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (6) , e202603624
Open AccessHistone methyltransferase DOT1L differentially affects the development of dendritic cell subsets
Dendritic cells (DCs) orchestrate immune responses. Their development is controlled by transcription factors, but epigenetic mechanisms remain poorly understood. DOT1L emerges as a key epigenetic regulator in immune cells. Mapping DOT1L-mediated histone H3K79 methylation in canonical DC subsets revealed that DOT1L modified common and DC subset–specific genes. Deletion of Dot1l in vivo or in vitro decreased myeloid progenitors and increased cDC2s, whereas cDC1s remained unchanged. In addition, in vitro deletion of Dot1l led to loss of plasmacytoid DCs (pDCs) and of IFNα production upon stimulation. Upon in vivo deletion, a decrease in pDCs was only observed after subsequent in vitro expansion. This difference was likely related to insufficient replication-mediated loss of H3K79 methylation in vivo within the time frame studied. Transcriptomes of Dot1l -KO DC subsets exhibited enrichment of antigen presentation pathways, and MHC class II surface levels were up-regulated in pDCs. Mechanistically, inhibition of DOT1L linked the observed effects to its methyltransferase activity. Together, our data indicate that in DCs DOT1L differentially affects the development of canonical subsets and suppresses antigen presentation pathways.
- Open Access
Histone methyltransferase DOT1L differentially affects the development of dendritic cell subsets
Dendritic cells (DCs) are important orchestrators of immune responses. Their development in the bone marrow is controlled by transcription factors, but epigenetic mechanisms remain poorly understood. DOT1L is emerging as a key epigenetic regulator in immune cells. By mapping DOT1L-mediated histone H3K79 methylation in canonical DC subsets, we observed that DOT1L modified common as well as DC subset-specific genes. In vitro- or in vivo- induced deletion of Dot1l followed by in vitro cell culture resulted in a decrease in myeloid progenitors and plasmacytoid DCs (pDCs) and an increase in cDC2s, while cDC1s remained unchanged. In vitro generated Dot1l- KO DCs were unable to produce IFNα upon stimulation. Moreover, transcriptomes of Dot1l -KO DC subsets exhibited enrichment of antigen presentation pathways and MHC class II surface levels were upregulated in pDCs. Mechanistically, inhibition of DOT1L linked the observed effects to its methyltransferase activity. Together, our data indicate that in DCs DOT1L differentially affects the development of canonical subsets and suppresses antigen presentation pathways.
Open AccessHistone methyltransferase DOT1L differentially affects the development of dendritic cell subsets
Dendritic cells (DCs) are important orchestrators of immune responses. Their development in the bone marrow is controlled by transcription factors, but epigenetic mechanisms remain poorly understood. DOT1L is emerging as a key epigenetic regulator in immune cells. By mapping DOT1L-mediated histone H3K79 methylation in canonical DC subsets, we observed that DOT1L modified common as well as DC subset-specific genes. In vitro- or in vivo- induced deletion of Dot1l followed by in vitro cell culture resulted in a decrease in myeloid progenitors and plasmacytoid DCs (pDCs) and an increase in cDC2s, while cDC1s remained unchanged. In vitro generated Dot1l- KO DCs were unable to produce IFNα upon stimulation. Moreover, transcriptomes of Dot1l -KO DC subsets exhibited enrichment of antigen presentation pathways and MHC class II surface levels were upregulated in pDCs. Mechanistically, inhibition of DOT1L linked the observed effects to its methyltransferase activity. Together, our data indicate that in DCs DOT1L differentially affects the development of canonical subsets and suppresses antigen presentation pathways.